The estimated Net Worth of Utpal Koppikar is at least $4.76 Million dollars as of 2 March 2023. Mr. Koppikar owns over 6,871 units of Atara Biotherapeutics Inc stock worth over $1,512,237 and over the last 6 years he sold ATRA stock worth over $705,394. In addition, he makes $2,540,170 as Chief Financial Officer at Atara Biotherapeutics Inc.
Sign up
Mr. Koppikar ATRA stock SEC Form 4 insiders trading
Utpal has made over 23 trades of the Atara Biotherapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 6,871 units of ATRA stock worth $24,942 on 2 March 2023.
The largest trade he's ever made was selling 6,871 units of Atara Biotherapeutics Inc stock on 2 March 2023 worth over $24,942. On average, Utpal trades about 2,439 units every 51 days since 2018. As of 2 March 2023 he still owns at least 181,978 units of Atara Biotherapeutics Inc stock.
You can see the complete history of Mr. Koppikar stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Utpal Koppikar biography
Utpal Koppikar serves as Chief Financial Officer of the company since June 2018. Prior to joining Atara, from June 2011 to June 2018, Mr. Koppikar held several senior financial leadership positions at Gilead Sciences, including as Vice President of Corporate and Operations Finance, responsible for R&D, corporate, G&A, process development and manufacturing, and strategic sourcing. Prior to Gilead, from January 2001 to June 2011, he served in multiple finance roles of increasing responsibility at Amgen. Mr. Koppikar earned his B.S. in aerospace engineering at the University of Maryland and received a M.S. in aeronautical and astronautical engineering from Stanford University. He also holds an MBA in finance and marketing from The Anderson School at UCLA.
What is the salary of Utpal Koppikar?
As the Chief Financial Officer of Atara Biotherapeutics Inc, the total compensation of Utpal Koppikar at Atara Biotherapeutics Inc is $2,540,170. There are 2 executives at Atara Biotherapeutics Inc getting paid more, with Pascal Touchon having the highest compensation of $6,637,310.
How old is Utpal Koppikar?
Utpal Koppikar is 49, he's been the Chief Financial Officer of Atara Biotherapeutics Inc since 2018. There are 14 older and 2 younger executives at Atara Biotherapeutics Inc. The oldest executive at Atara Biotherapeutics Inc is Roy Baynes, 65, who is the Independent Director.
What's Utpal Koppikar's mailing address?
Utpal's mailing address filed with the SEC is C/O C4 THERAPEUTICS, INC., 490 ARSENAL WAY #120, WATERTOWN, MA, 02472.
Insiders trading at Atara Biotherapeutics Inc
Over the last 10 years, insiders at Atara Biotherapeutics Inc have traded over $58,305,463 worth of Atara Biotherapeutics Inc stock and bought 1,293,860 units worth $5,821,259 . The most active insiders traders include Joel S Marcus, Eric Dobmeier, and Ronald C Jr Renaud. On average, Atara Biotherapeutics Inc executives and independent directors trade stock every 9 days with the average trade being worth of $99,047. The most recent stock trade was executed by Pascal Touchon on 16 August 2024, trading 3,038 units of ATRA stock currently worth $20,142.
What does Atara Biotherapeutics Inc do?
we launched atara biotherapeutics in august 2012 to help patients combat cancer, kidney disease and other illnesses. our research is based on groundbreaking discoveries regarding the ability of activin, myostatin and other growth factors to change the course of disease progression. our goal is to help patients such as atara ciechanover, our company’s namesake, who suffered from cancer before passing away in 2012. we aim to empower patients to fight their illnesses with better treatment options. atara biotherapeutics is developing several innovative product candidates, including pinta 745, stm 434 and ata 842, and is collaborating with memorial sloan kettering cancer center (msk) in the development of three t-cell product candidates: epstein-barr virus (ebv)-targeted cytotoxic t lymphocytes (ctls), cytomegalovirus (cmv)-targeted ctls, and wilms tumor 1 (wt1)-targeted ctls. each product candidate is designed to address the underlying mechanisms of disease to treat conditions which have
What does Atara Biotherapeutics Inc's logo look like?
Complete history of Mr. Koppikar stock trades at Atara Biotherapeutics Inc, Flexion Therapeutics Inc, and C4 Therapeutics
Atara Biotherapeutics Inc executives and stock owners
Atara Biotherapeutics Inc executives and other stock owners filed with the SEC include:
-
Pascal Touchon,
President, Chief Executive Officer, Director -
Joseph Newell,
Chief Operating Officer, Executive Vice President -
Utpal Koppikar,
Chief Financial Officer -
Dr. Pascal Touchon D.V.M.,
Pres, CEO & Director -
Dr. Kristin Yarema Ph.D.,
SVP & Chief Commercial Officer -
Joseph Newell,
Exec. VP & COO -
Utpal Koppikar,
CFO & SVP -
Dr. Jakob Dupont,
Head of Global R&D -
Carol Gallagher,
Lead Independent Director -
Eric Dobmeier,
Independent Director -
Matthew Fust,
Independent Director -
Beth Seidenberg,
Independent Director -
William Heiden,
Independent Director -
Roy Baynes,
Independent Director -
Eric Hyllengren,
Vice President, Investor Relations & Finance -
Maria Roncarolo,
Director -
Kristin Yarema,
Chief Commercial Officer -
K. Amar Murugan,
Senior Vice President, General Counsel -
Ronald Renaud,
Chairman of the Board -
Amie Krause,
Chief People Officer -
Kerry Beth Daly,
Head of Corp. Communications -
K. Amar Murugan,
Sr. VP & Gen. Counsel -
Dr. Anhco Nguyen,
Chief Scientific Officer -
Heather D Turner,
VP, General Counsel & Sec. -
Joel S Marcus,
Director -
Gad Soffer,
Chief Operating Officer -
Isaac E. Ciechanover,
Chief Executive Officer -
Derrell Porter,
SVP, Head of Global Commercial -
Joe Newell,
Chief Operations Officer -
Mitchall G. Clark,
Chief R & QA Officer -
Christopher Haqq,
Chief Medical Officer -
Mina Kim,
Senior VP & General Counsel -
Eckard Weber,
Director -
Viii Associates, L.P.Blair ...,
-
Perkins Caufield & Byers Xv...,
-
Partners Viii, L.P.Blair Ja...,
-
John Mcgrath,
Chief Financial Officer -
Dietmar Berger,
Global Head of R&D -
Ameet Mallik,
-
Jakob Dupont,
EVP, Head of R&D -
Charlene A. Banard,
EVP, Chief Technical Officer -
Amar Murugan,
EVP, Chief Legal Officer -
Jill Henrich,
EVP, Global Head RA & Quality -
Manher Joshi,
EVP, Chief Medical Officer -
Anh Co Nguyen,
President and CEO